StatLab Medical Products, a McKinney-based leader in medical diagnostic supplies and equipment, is set to acquire Diapath S.p.A., an Italian manufacturer specializing in histology and cytology products. The move is part of StatLab’s strategy to expand its global footprint and bolster its product offerings across the anatomic pathology workflow.

The company said the integration of Diapath, with its “innovative equipment offerings, manufacturing capabilities, and established customer base” across Europe, Asia-Pacific, Middle East and Africa, and Latin America will significantly expand StatLab’s market access. This acquisition positions StatLab to enhance its global leadership in medical diagnostics and unlock substantial growth potential. No financial details of the transaction were disclosed.

The acquisition is slated to close during the third quarter of 2024. Upon completion, Diapath founder Vladimiro Bergamini will transition to a senior advisor role at StatLab, while Chief Operating Officer Alberto Battistel will join StatLab’s executive leadership team and lead the Diapath business unit as its managing director.

Strategic growth and market expansion

StatLab CEO Sung-Dae Hong

CEO Sung-Dae Hong, who took the StatLab helm this time last year, brings decades of experience in driving strategic growth through manufacturing and M&A. “This combination is a pivotal milestone in our strategy to manufacture the full array of products supporting the entire anatomic pathology workflow,” Hong said in a statement, emphasizing the partnership’s potential to drive innovation and expand Diapath’s brand globally. He added that the acquisition will also enhance StatLab’s European market access for slides, cassettes, and printers.

‘Shared commitment to growth and innovation’

Founded in 1997 by Bergamini, Diapath is headquartered in Martinengo, near Bergamo, Italy. Over the past 27 years, the company has evolved from a consumables manufacturer into a developer of advanced histology instruments, including tissue processors, stainers, embedding centers, and microtomes. Diapath’s equipment portfolio, known for its cutting-edge Italian design and quality, includes the award-winning Donatello automatic tissue processor and the T-Filler Automatic Formalin dispenser, which enhances lab safety by protecting technicians from chemical exposure.

“The decision to join StatLab is driven by our shared commitment to growth and innovation to meet customer needs,” said Bergamini. “Our combined company will be uniquely positioned to further expand Diapath’s brand and business, together transforming the anatomic pathology market through innovative development and manufacturing.

“The decision to join StatLab reflects our shared commitment to growth and innovation,” said Bergamini. The Diapath founder says that the merger will position the combined company to expand Diapath’s brand and transform the anatomic pathology market through innovative development and manufacturing.

Bergamini noted that the merger would allow the combined company to expand Diapath’s brand and impact the anatomic pathology market through innovative development and manufacturing. He looks forward to leveraging the companies’ combined capabilities to “capture new business opportunities.”

The 2022 acquisition of Wales-based CellPath Ltd.—known for injection molding manufacturing of histology supplies—served as a catalyst for its new 35,000-square-foot manufacturing facility in Arlington.

StatLab, established in 1976, has grown into a major player in the medical diagnostics field, expanding its product line and manufacturing capabilities through strategic acquisitions. In 2022, it acquired UK-based CellPath Ltd., enhancing its manufacturing capabilities and presence in Europe. In 2023, the company opened a new U.S. manufacturing facility in Arlington to meet increased production demands.

StatLab’s growth has been supported by investments from private equity firms such as Linden Capital Partners and Audax Private Equity, facilitating its expansion through acquisitions and infrastructure development.

Get on the list.
Dallas Innovates, every day.

Sign up to keep your eye on what’s new and next in Dallas-Fort Worth, every day.